On June 25, 2024, Beijing Bohui Innovation Biotechnology Group (300318.SZ) conducted a specific survey on the research and development progress of Hebei Bohui and Guangdong Weilun's new products (fibrous origin, 8 indicators, chromatographic static propylene, etc.). The company responded that human fibronectin is conducting stability and preclinical studies. The production registration application work for human clotting factor VIII is underway. The new process of chromatographic static propylene is undergoing scaling-up trial research.
博晖创新(300318.SZ)：人凝血因子VIII正在准备生产注册申报工作
Beijing Bohui Innovation Biotechnology Group (300318.SZ): The production registration application for human coagulation factor VIII is being prepared.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.